Trans-acting transcriptional factors
AssigneeDana-Farber Cancer Institute, Inc.
InventorsWilliam A. Haseltine, Joseph G. Sodrowski, Craig A. Rosen
Life of this patent
Estimating the term…
Loading patent…
AssigneeDana-Farber Cancer Institute, Inc.
InventorsWilliam A. Haseltine, Joseph G. Sodrowski, Craig A. Rosen
Estimating the term…
This invention describes the discovery of a novel phenomena in retrovirus transcription, namely transcriptional trans-activation. Described herein are novel trans-acting factors which may be employed to enhance the production of heterologous genes. Described is a novel trans-acting directing gene, designated herein as the "luk" gene and the 35,000 to 45,000, more specifically about 42,000 dalton molecular weight protein encoded thereby. The present invention demonstrates the LTR elements of HTLV can function as transcriptional promoters for heterologous genes on both unintegrated and integrated DNA. In general, the HTLV-1 LTR is a stronger promoter than is the HLTV-II LTR in its requirements for cellular and/or viral trans-acting factors in order to function efficiently. HTLV infection results in the production of trans-acting factors that dramatically increase the rate of HTLV LTR-promoted transcription.
A vector comprising a DNA sequence coding for a desired gene product, a DNA sequence coding for an HTLV-I or -II trans-acting factor and a portion of an HTLV-I or -II LTR responsive to the HTLV trans-acting factor.
A gene expression system comprising an expression vector and a DNA segment coding for an HTLV-I or -II trans-acting factor, wherein the expression vector comprises a preselected gene coding for a desired product, which is under the control of an HTLV-I or -II regulatory element responsive to the trans-acting factor and wherein the expression vector codes for a product other than a complete HLTV virus.
A method for stimulating the production of a gene product, which comprises:
Dependencies are inferred from the claim text.